Skip to main contentBack to Top

Researchers in the Cancer Immunology, Inflammation and Tolerance program use a range of techniques to study how the immune system influences tumorigenesis and cancer therapy. The immune system can inhibit or promote tumor progression in local tissues where pre-malignancies form. Major program themes are to elucidate

  • How pre-malignancies create and sustain local immunologic tolerance necessary for tumor formation
  • How to destroy local tolerance that protects tumors from natural and vaccine-induced anti-tumor immunity.

The scientific rationale for this dual approach is that pre-malignant cells create and sustain tolerance during tumor progression, while breaking tumor-associated tolerance is necessary for successful anti-tumor treatment. Hence, program goals are to elucidate molecular and cellular pathways at sites of inflammation that promote or break immune tolerance using pre-clinical mouse models of tumor progression and autoimmune syndromes, and developing novel immunotherapies to treat these syndromes more effectively by targeting tolerance pathways. To this end, program faculty also engage in promoting pre-clinical research and early-phase clinical trials of novel vaccine adjuvants to improve cancer immunotherapy, in some cases with corporate partners.

To pursue these focused research themes and scientific goals, program faculty employ many state-of-the-art techniques, facilities, and unique resources, including flow cytometric sorting and analysis, a range of molecular imaging techniques, genomic analysis, and genetically modified mouse strains. Future program development will build on existing CIT program strengths by recruiting new investigators with expertise in inflammation, immunological, and metabolic research to complement current research focused on regulation of adaptive immunity.


photo of Yan Cui, PhD

Yan Cui, PhD

  • Professor
photo of Yukai He, MD, PhD

Yukai He, MD, PhD

  • Professor

I was trained as a physician, but has been fascinated by how our body’s immune system has been so effective to control not only microbial infections, but also cancer cells. We had studied the basic mechanism of how cancer vaccines activated immune responses and applied the vaccine design technologies into developing liver cancer vaccines. Over the last decade, research in my lab has been focusing on identifying novel T cell receptors (TCR) and on developing new chimeric antigen receptors (CAR) for liver cancer immunotherapy. We are fortunate that our research has been continuously funded by NCI/NIH grants. Our goal is to engineer immune T cells to become potent and targeted fighters to eliminate cancer cells and cure cancer patients.

photo of Theodore S. Johnson, MD, PhD

Theodore S. Johnson, MD, PhD

  • Associate Professor
photo of Santhakumar Manicassamy, PhD

Santhakumar Manicassamy, PhD

  • Associate Professor
photo of David Munn, MD

David Munn, MD

  • Professor
photo of Rafal Pacholczyk, PhD

Rafal Pacholczyk, PhD

  • Assistant Professor
photo of Gang Zhou, PhD

Gang Zhou, PhD

  • Associate Professor

Associate Members

photo of Zoya C. Kurago, DDS, PhD

Zoya C. Kurago, DDS, PhD

  • Associate Professor
photo of Kebin Liu, PhD

Kebin Liu, PhD

  • Professor
photo of Nagendra Singh, PhD

Nagendra Singh, PhD

  • Assistant Professor

Cancer Research News


Georgia Cancer Center welcomes associate director of basic science

“Getting to meet incredible physicians and scientists and learn about the fabulous science that takes place here has been the best part of my job so far,” Kaur said of her new position as associate director of basic science at the Georgia Cancer Center.

man with glasses in jacket standing in front of dry erase board

Augusta University physicist joins international team to study how cells move

“Cells are very complicated systems that we are still working to understand, so we had to find a way to simplify it," said Abdul N. Malmi-Kakkada, PhD.

Man in black coat and shirt leans against building

Moore recognized with AACR Minorities in Cancer Research award

Dr. Justin Xavier Moore has been recognized with an American Association for Cancer Research Minorities in Cancer Research award.

Colon Cancer Awareness Month ribbon in front of picture of the Georgia Cancer Center

Oncology professor answers questions regarding National Colon Cancer Awareness Month

"Colon cancer is largely preventable if patients undergo screening tests, like a surveillance colonoscopy starting at 45 years or earlier depending on family history."